According to Pfizer, the third dose is 36% more effective against the Omicron variant.
While many children are receiving the second dose of the vaccine against covid-19 in Brazil, pharmaceutical Pfizer has already announced results of a booster dose in the children’s group. With the analysis of 140 children aged 5 to 11 years who received the third stage, the trial in phase 2/3 verified the safety and protection of the immunizer.
THIRD DOSE IS 36 TIMES MORE EFFECTIVE AGAINST OMICRON IN CHILDREN
“Serum antibodies induced by a third dose neutralize the Omicron variant of SARS-CoV-2 in this age group”, informed the pharmacist. As a result of the test, the effectiveness of the additional dose is 36 times more effective against Omicron in children compared to the second application.
The Pfizer study still needs to be peer-reviewed, but according to the drugmaker, the results show a robust immune response, which demonstrates “the potential role of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group”.
With more than 10 thousand participants under the age of 12, the study identified no new side effects. Overall, the immunizer was well tolerated. with the data, Pfizer will ship to Food and Drug Administration (FDA) a request for authorization of the emergency use of the third dose in the infant group.
Source: Recreio
